Evidence map›Paper›PMID 18559558›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2008

Overexpression of CDC25B and LAMC2 mRNA and protein in esophageal squamous cell carcinomas and premalignant lesions in subjects from a high-risk population in China.

Jian-Zhong Shou, Nan Hu, Mikiko Takikita, Mark J Roth, Laura Lee Johnson, Carol Giffen, Quan-Hong Wang, Chaoyu Wang, Yuan Wang, Hua Su and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Identification of Therapeutic and Prognostic Biomarkers of Lamin C (LAMC) Family Members in Head and Neck Squamous Cell Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  10. Article
  11. The prognostic role of FZD6 in esophageal squamous cell carcinoma patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Article
  12. Article
  13. Article
  14. PLCE1 mRNA and protein expression and survival of patients with esophageal squamous cell carcinoma and gastric adenocarcinoma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Global gene expression profiling and validation in esophageal squamous cell carcinoma and its association with clinical phenotypes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 4 countries.

Jian-Zhong ShouPathology Laboratory, Advanced Technology Center, National Cancer Institute, Bethesda, MD 20892-4605, USA.
Nan Hu
Mikiko Takikita
Mark J Roth
Laura Lee Johnson
Carol Giffen
Quan-Hong Wang
Chaoyu Wang
Yuan Wang
Hua Su
Li-Hui Kong
Michael R Emmert-Buck
Alisa M Goldstein
Stephen M Hewitt
Philip R Taylor
National Cancer Institute · UAShanxi Provincial Cancer Hospital · CNCancer Institute (WIA) · INDivision of Cancer Epidemiology and GeneticsCenter for Cancer Research · USChinese Academy of Medical Sciences & Peking Union Medical College · CNInformation Management Services · USNational Center for Complementary and Integrative Health · US

Funding

Tissue Array Research ProgramZICBC010923 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HEWITT, STEPHEN · 2009 to 2014
$4.7M
UGI Cancer Genetic StudiesZ01CP000150 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI TAYLOR, PHILIP · 2005 to 2008
$1.8M
Molecular Pathology of CancerZ01SC010437 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI EMMERT-BUCK, MICHAEL R · 2002 to 2008
$1.4M
Upper Gastrointestinal Cancer StudiesZ01CP000185 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI DAWSEY, SANFORD M · 2005 to 2008
$1.4M
Intramural NIH HHS Z01 CP000150
6 · The paper itself

Abstract

Molecular events associated with the initiation and progression of esophageal squamous cell carcinoma (ESCC) remain poorly understood but likely hold the key to effective early detection approaches for this almost invariably fatal cancer. CDC25B and LAMC2 are two promising early detection candidates emerging from new molecular studies of ESCC. To further elucidate the role of these two genes in esophageal carcinogenesis, we did a series of studies to (a) confirm RNA overexpression, (b) establish the prevalence of protein overexpression, (c) relate protein overexpression to survival, and (d) explore their potential as early detection biomarkers. Results of these studies indicated that CDC25B mRNA was overexpressed (>/=2-fold overexpression in tumor compared with normal) in 64% of the 73 ESCC cases evaluated, whereas LAMC2 mRNA was overexpressed in 89% of cases. CDC25B protein expression was categorized as positive in 59% (144 of 243) of ESCC cases on a tumor tissue microarray, and nonnegative LAMC2 patterns of protein expression were observed in 82% (225 of 275) of cases. Multivariate-adjusted proportional hazard regression models showed no association between CDC25B protein expression score and risk of death [hazard ratio (HR) for each unit increase in expression score, 1.00; P = 0.90]; however, several of the LAMC2 protein expression patterns strongly predicted survival. Using the cytoplasmic pattern as the reference (the pattern with the lowest mortality), cases with a diffuse pattern had a 254% increased risk of death (HR, 3.52; P = 0.007), cases with no LAMC2 expression had a 169% increased risk of death (HR, 2.69; P = 0.009), and cases with a peripheral pattern had a 130% greater risk of death (HR, 2.30; P = 0.02). CDC25B protein expression scores in subjects with esophageal biopsies diagnosed as normal (n = 35), dysplastic (n = 23), or ESCC (n = 32) increased significantly with morphologic progression. For LAMC2, all normal and dysplastic patients had a continuous pattern of protein expression, whereas all ESCCs showed alternative, noncontinuous patterns. This series of studies showed that both CDC25B and LAMC2 overexpress RNA and protein in a significant majority of ESCC cases. The strong relation of LAMC2 pattern of protein expression to survival suggests a role in prognosis, whereas the association of CDC25B with morphologic progression indicates a potential role as an early detection marker.

Indexed as

Carcinoma, Squamous Cellcdc25 PhosphatasesChinaEsophageal NeoplasmsFemaleGene Expression ProfilingHumansImmunoenzyme TechniquesLamininLinear ModelsMaleMiddle AgedPrecancerous ConditionsProportional Hazards ModelsProtein Array AnalysisReverse Transcriptase Polymerase Chain ReactionCDC25B protein, humancdc25 PhosphatasesLAMC2 protein, humanLamininRNA, Messenger

Identifiers

PMID18559558
PMCPMC2729558
OpenAlexW2095636742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.